Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors
​Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...
145 Views
Attovia Therapeutics (ATTO US): Synthetic Expert Call Transcript (29 Jul 2026)
The ATTOBODY platform’s technical edge lies in its spatially optimized, biparatopic VHH architecture, which routinely achieves picomolar binding...
100 Views
Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO
​Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...
126 Views
Primer: Attovia Therapeutics (ATTO US) - Jul 2026
Attovia Therapeutics is a clinical-stage biotechnology company with a proprietary ATTOBODY™ platform designed to develop novel, multi-specific...
98 Views